Table 2.

Clinical parameters which should be monitored to determine treatment efficacy and disease progression [10, 47]

Hematologic measurements	Renal measurements	Other measurements
Complete blood counts and electrolyte panels should be monitored frequently, even daily	Proteinuria should be assessed via random urine protein and creatinine quantification	Assessment of changes in the need for transfusions (red cell and platelet) should be completed, particularly within first 100 days post-transplant
Schistocytes should be assessed routinely via peripheral blood smears	Kidney function monitoring should be assessed to monitor signs of acute kidney injury	Routine monitoring for viremias such as BK virus and adenovirus is required
Lactate dehydrogenase levels should be measured twice weekly		Blood pressure measurements should be routinely captured to monitor for hypertension
Serum soluble C5b-9 concentrations should be assessed, if feasible		Cardiac monitoring via echocardiography should be performed in symptomatic patients with suspected/confirmed thrombotic microangiopathy, particularly in hypoxemic patients requiring intensive care
		Assessment of oxygen requirements (e.g., unexplained increase in oxygen needs or improvements following treatment)
		If feasible, biopsies can be considered as required, following strict risk–benefit assessments